NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
05/24/2022
Back to search
Official data from USPTO
CRISPR THERAPEUTICS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
CRISPR THERAPEUTICS
ST13
US500000090715256Class
41, 42
Filing
90715256
Registration
6724517
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
13
Latest update
09/03/2023
Trademark type
Word
Nice classes
41, 42
Filing date
05/17/2021
Registration date
05/24/2022
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
05/24/2022
Last transaction
09/03/2023
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
First use anywhere
11/01/2013
First use in commerce
11/01/2013
Drawing code
4
Owner type
99
Owner location
ZUG V8, CH
Examiner
BAL,KAMAL S
Law office
N10
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
CRISPR Therapeutics AG
Representatives
TIFFANY D. GEHRKE MARSHALL, GERSTEIN & BORUN LLP
Technical classification
Nice Classes
Class 41Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 41
Education servicesproviding on-line non-downloadable articles and newsletters in the field of pharmaceuticalsgeneticsgenome editinggene editinggenome engineeringgene modulationtranscriptional regulationtranscriptional modulationgenetic diseasesgene therapy and cell therapy
Class 42
Scientific research and developmentgene editing for researching and developing human cells and pharmaceuticals; research and development of therapeutics pharmaceuticals using gene editing; pharmaceuticalmedicalscientificbiopharmaceutical research and development; medical laboratory services; scientific laboratory services; custom cell-line engineering services; medical and scientific research in the fields of pharmaceuticalsgeneticsgenome editinggene editinggenome engineeringgene modulationtranscriptional regulationtranscriptional modulationgenetic diseasesgene therapy and cell therapy; providing medical research and scientific research information in the fields of pharmaceuticalsgeneticsgenome editinggene editinggenome engineeringgene modulationtranscriptional regulationtranscriptional modulationgenetic diseasesgene therapy and cell therapy; scientific research and development services relating to targeting genetic therapies to individuals
Publications
History of USPTO decisions and trademark events.
13 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
05/24/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
02/22/2022
PUBO
PUBLISHED FOR OPPOSITION
02/22/2022
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
02/02/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
01/19/2022
XAEC
EXAMINER'S AMENDMENT ENTERED
01/19/2022
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
01/19/2022
GNEA
EXAMINERS AMENDMENT E-MAILED
01/19/2022
CNEA
EXAMINERS AMENDMENT -WRITTEN
01/19/2022
DOCK
ASSIGNED TO EXAMINER
01/11/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
08/14/2021
NWAP
NEW APPLICATION ENTERED
05/20/2021
Continuous trademark protection
Get notified about every new filing that threatens CRISPR THERAPEUTICS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.